Carcinogenesis, Vol. 21, No. 12, 2225-2235,
December 2000
© 2000 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells
1 Center for Cancer Causation and Prevention, AMC Cancer Research Center, Denver, CO 80214 and
2 University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
Recently, we observed that epidermal growth factor receptor (EGFR or erbB1) endocytosis and associated mitogenic signaling occur in human prostate cancer (PCA) cells, suggesting that erbB1 endocytosis might be involved in advanced and androgen-independent PCA growth. Based on these findings, and the fact that aberrant expression of erbB family members is common in human prostatic intraepithelial neoplasia and invasive PCA, we reasoned that impairment of erbB1 endocytosis and associated mitogenic signaling might inhibit PCA growth. Inositol hexaphosphate (IP6) interacts with plasma membrane clathrin-associated protein complex 2 (AP2) and inhibits phosphatidylinositol 3-kinase (PI3K). As these are essential components of receptor-mediated and fluid-phase endocytosis, respectively, we reasoned that IP6 might impair erbB1 endocytosis and associated signaling in human PCA cells, leading to their growth inhibition. IP6 strongly to completely inhibited (26–100%; P < 0.05) transforming growth factor 
-induced binding of activated erbB1 to AP2 in human PCA DU145 cells, demonstrating the impairment of the initial step in ligand-induced erbB1 endocytosis. IP6 treatment of cells resulted in a dose-dependent increase (1.8- to 7.7-fold compared with cells treated with ligand alone; P < 0.05) in levels of activated erbB1. These two findings suggest that the inhibitory effect of IP6 on receptor endocytosis is independent of its lack of effect on ligand-induced erbB1 activation. These effects of IP6, however, were associated with strong inhibition of ligand-induced Shc phosphorylation (77–84% decrease; P < 0.05) and its binding to erbB1 (58–100% decrease; P < 0.05). IP6 also significantly and dose-dependently inhibited fluid-phase endocytosis (19–52%; P < 0.05). It inhibited PI3K–AKT signaling pathway as an upstream response in its effect on the inhibition of fluid-phase endocytosis. The inhibition of erbB1 receptor and fluid-phase endocytosis, and associated signaling by IP6, was corroborated by very strong to complete inhibition (70–100%; P < 0.05) of extracellular signal-regulated protein kinase 1/2 activation by IP6. IP6 significantly (P < 0.05) inhibited anchorage-dependent and -independent inhibition (50–100% and 30–75%, respectively) in DU145 cells. Targeting the impairment of erbB1 endocytosis and associated mitogenic signaling by IP6 in advanced and androgen-independent human PCA DU145 cells could be a useful approach for treating PCA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Raina, S. Rajamanickam, R. P. Singh, and R. Agarwal Chemopreventive Efficacy of Inositol Hexaphosphate against Prostate Tumor Growth and Progression in TRAMP Mice Clin. Cancer Res., May 15, 2008; 14(10): 3177 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Jeffery, S. F. Madden, P. A. McGettigan, G. Perriere, A. C. Culhane, and D. G. Higgins Integrating transcription factor binding site information with gene expression datasets Bioinformatics, February 1, 2007; 23(3): 298 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Vucenik, A. Passaniti, M. I. Vitolo, K. Tantivejkul, P. Eggleton, and A. M. Shamsuddin Anti-angiogenic activity of inositol hexaphosphate (IP6) Carcinogenesis, November 1, 2004; 25(11): 2115 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, G. Sharma, G. U. Mallikarjuna, S. Dhanalakshmi, C. Agarwal, and R. Agarwal In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate: Induction of Insulin-Like Growth Factor Binding Protein-3 and Inhibition of Vascular Endothelial Growth Factor Clin. Cancer Res., January 1, 2004; 10(1): 244 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Vucenik and A. M. Shamsuddin Cancer Inhibition by Inositol Hexaphosphate (IP6) and Inositol: From Laboratory to Clinic J. Nutr., November 1, 2003; 133(11): 3778S - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Singh, C. Agarwal, and R. Agarwal Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes Carcinogenesis, March 1, 2003; 24(3): 555 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ferry, M. Matsuda, H. Yoshida, and M. Hirata Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NF{kappa}B-mediated cell survival pathway Carcinogenesis, December 1, 2002; 23(12): 2031 - 2041. [Abstract] [Full Text] [PDF]
|
|